Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

You may not be if

• Histologically or cytologically confirmed to have recurrent, or metastatic breast cancer.
• Measurable disease (revised RECIST, version 1.1).
• Hormone receptor (ER/PR) positive or negative, HER2 negative.
• Subjects were eligible for the study regardless of their previous lines of endocrine therapy.
• No prior chemotherapy is allowed in metastatic disease.
• Subjects who administrated the last dose of taxane class drug ≥12months ago as from the first administration day.
• ECOG performance status ≤1.
• Neuropathy grade \<2.
• Subjects with central nervous system metastasis should be excluded.